Fertility Drugs Market Size, Share & Industry Analysis, By Drug Class (Ovulation Induction Agents, Gonadotropins, hCG-based Trigger Drugs, GnRH Agonists, and Progesterone/Luteal Phase Support Drugs), By Drug (Clomiphene Citrate, Letrozole, FSH, hCG, Progesterone, Cetrorelix, and Ganirelix), By Treatment (ART/IVF Cycle Support, Non-ART Female Fertility Treatment, and Male Fertility Treatment), By Route of Administration (Injectable, Oral, Vaginal, and Others), By End User (Fertility Clinics, Hospitals, Specialty Clinics, and Homecare Settings), and Regional Forecast, 2026-2034

The global fertility drugs market size was valued at USD 3.05 billion in 2025. The market is projected to grow from USD 3.24 billion in 2026 to USD 5.25 billion by 2034, exhibiting a CAGR of 6.22% during the forecast period.

The global fertility drugs market includes medicines used to improve reproductive outcomes by regulating hormones, stimulating ovulation, supporting egg development, and improving the success of assisted reproduction procedures such as IVF and IUI. These drugs are mainly used in women with ovulatory disorders, unexplained infertility, polycystic ovary syndrome, diminished ovarian reserve, and in patients undergoing controlled ovarian stimulation. The market is gaining steady importance as infertility rates remain high, parenthood is increasingly delayed, and more patients seek medical support to improve their chances of conception.

Furthermore, government support and initiatives to expand access to fertility treatments are further intensifying market growth potential.

• For instance, in October 2025, Merck KGaA collaborated with the U.S. government to expand access to its IVF therapy portfolio, including Gonal-f, Ovidrel, and Cetrotide, at significantly reduced prices for eligible patients with prescriptions. The development highlighted how key companies are focusing on affordability and access, which can support wider treatment adoption and strengthen demand for fertility drugs.

Key players, such as Merck KGaA, Ferring B.V., Organon & Co., and IBSA Institut Biochimique SA, are actively pursuing pipeline development, regulatory approvals, strategic collaborations and acquisitions, and investment initiatives to expand their market presence.

FERTILITY DRUGS MARKET TRENDS

Increasing Awareness and Early Diagnosis of Infertility is a Prominent Trend Observed

As infertility becomes a common reproductive health concern across both developed and emerging countries, the global market is anticipated to grow. A large patient population experiences infertility during their lifetime, showing that infertility is not limited to a specific region or income group. This large patient pool is increasing the need for ovulation induction drugs, gonadotropins, hormonal therapies, and luteal phase support medicines used in fertility treatment cycles. As more couples delay parenthood and seek medical help for conception, fertility clinics are using these drugs more frequently to improve egg development, regulate ovulation, and support IVF and IUI procedures. This directly supports steady demand growth for fertility drug therapies worldwide.

• For instance, in January 2026, the Centers for Disease Control and Prevention (CDC) reported National Survey of Family Growth data showing that 13.4% of women aged 15-49 years (of all marital statuses) have impaired fecundity, meaning they are not surgically sterile but have difficulty becoming pregnant or carrying a pregnancy to term.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Maternal Age and Delayed Parenthood is Boosting Product Demand

The global market is gaining momentum as more women and couples are planning pregnancy at a later age due to education, career priorities, family planning, and changing family preferences. As maternal age increases, natural fertility generally declines, which raises the need for medical support through ovulation induction drugs, gonadotropins, and hormonal therapies used in assisted reproductive procedures. This shift directly increases the number of patients seeking treatments at fertility clinics for IVF, IUI, and controlled ovarian stimulation cycles. As a result, delayed parenthood is creating a larger treatment-seeking population and supporting demand for the product across mature and emerging healthcare markets. Additionally, an expanding product pipeline is bringing forward innovative technologies and driving the global fertility drugs market growth.

• For instance, in December 2025, Granata Bio reported strong enrollment momentum in its pivotal Phase III GRACE study of an investigational gonadotropin for assisted reproductive technology. The program is focused on expanding patient choice and improving access to fertility care for people pursuing IVF. This development highlighted how companies are advancing fertility drug options as demand for assisted reproductive treatment continues to rise.

MARKET RESTRAINTS

Safety Concerns Associated with Hormonal Stimulation Therapies to Restrict Market Growth

The growth of the global fertility drugs market is restrained by safety concerns linked to hormonal stimulation therapies, especially gonadotropins used in IVF and controlled ovarian stimulation cycles. These safety risks can reduce patient confidence, increase treatment discontinuation, and limit drug adoption in regions where fertility care infrastructure and monitoring facilities are less developed. FDA-approved labeling for Gonal-f states that the product is capable of causing ovarian hyperstimulation syndrome, with or without pulmonary or vascular complications, and that gonadotropin therapy requires appropriate monitoring facilities.

• For instance, in November 2025, the Human Fertilization and Embryology Authority (HFEA) reported that U.K. fertility clinics recorded 224 Grade B incidents during the 2024/25 reporting period, including 68 cases of severe and critical ovarian hyperstimulation syndrome (OHSS). Since OHSS is a known adverse reaction to fertility drugs used to stimulate egg production, these reported incidents highlight the safety and monitoring risks associated with fertility drug use.

MARKET OPPORTUNITIES

Expanding Employer-sponsored and Insurance Coverage to Create New Growth Opportunities

The global market is expected to benefit from the rising inclusion of fertility treatment in employer-sponsored and insurance-based healthcare benefits. Fertility treatment is often expensive. When employers and insurers provide fertility benefits, the out-of-pocket burden for patients decreases, which makes treatment more affordable and encourages more couples to begin or continue fertility care. This directly increases the use of fertility drugs in assisted reproductive treatment cycles. As more companies treat fertility support as part of employee health and family-building benefits, the addressable patient population for fertility medications is likely to expand, creating a strong growth opportunity for manufacturers and fertility care providers.

• For instance, in October 2025, Carrot launched its Carrot Rx Flex Program for U.S. employers to provide fertility pharmacy benefits with greater price transparency and cost savings. The company stated that medication costs are one of the biggest barriers to fertility care and that employers offering coverage for three IVF cycles could save an additional USD 15,000 per employee per year by using Carrot Rx as a complementary pharmacy solution.

MARKET CHALLENGES

Uncertain Treatment Success Rates and Increasing Emotional and Financial Burden of Repeated Cycles Hinder Market Growth

The global fertility drugs market faces a major challenge due to the uncertain success rate of fertility treatment cycles. These treatments do not guarantee pregnancy or live birth. Success rates vary by age, infertility diagnosis, embryo quality, ovarian response, and previous treatment history, which means many patients may require repeated cycles before achieving a successful outcome. This increases the total cost of fertility care, as patients often need to purchase fertility medicines multiple times across different treatment cycles. The burden of repeated treatment cycles can also create emotional stress, financial pressure, and treatment fatigue, causing some patients to delay or discontinue therapy.

• For instance, in July 2023, the National Institutes of Health (NIH) published an article titled ‘Patient and professional perspectives about using in vitro fertilisation add-ons in the U.K. and Australia: a qualitative study’ which reported that IVF add-ons are controversial due to limited evidence supporting their efficacy and safety, while also adding extra financial cost for patients. The study highlighted that patients and professionals remain concerned about whether these add-ons truly improve outcomes, although they are still commonly considered during IVF treatment.

Segmentation Analysis

By Drug Class

Gonadotropins Segment Dominated Due to Its Central Role in Controlled Ovarian Stimulation

Based on drug class, the market is categorized into ovulation induction agents, gonadotropins, hCG-based trigger drugs, GnRH Agonists, GnRH antagonists, progesterone/luteal phase support drugs, and others.

The gonadotropins segment dominated the market, as it is one of the most important drug groups used in IVF and other assisted reproductive procedures. These medications directly stimulate the ovaries to develop multiple follicles, which increases the number of eggs available for retrieval and improves the chances of successful fertilization. Since controlled ovarian stimulation is a core step in IVF cycles, fertility specialists commonly rely on gonadotropins for patients with ovulatory disorders, unexplained infertility, reduced ovarian response, and ART-based treatment needs. Their strong clinical use, higher treatment cost compared with oral drugs, and repeated use across multiple IVF cycles support their leading revenue contribution to the market.

• For instance, in July 2025, Ferring Pharmaceuticals announced ESHRE data showing that conventional FSH dosing for Rekovelle matched follitropin alfa in IVF/ICSI cycles, with comparable ovarian response and clinical pregnancy rates. This highlights the continued clinical importance of gonadotropin-based ovarian stimulation in fertility treatment protocols.

The others segment is expected to grow at a CAGR of 8.04% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Drug

FSH Segment Dominated Due to Its High Use in Follicle Development and IVF Protocols

Based on drug, the market is segmented into clomiphene citrate, letrozole, FSH, hMG, hCG, progesterone, cetrorelix, ganirelix, leuprolide, triptorelin, and others.

In 2025, the FSH segment dominated the market, as it is widely used to stimulate follicle development in women undergoing fertility treatment. In IVF cycles, the objective is to develop multiple mature follicles so that more eggs can be retrieved and fertilized, and FSH directly supports this process. Compared with some supportive fertility drugs, FSH products are used at a higher value per cycle and often require multiple doses, which increases their revenue share. Recombinant and biosimilar FSH products are also gaining attention as they support consistent dosing, improve treatment planning, and address affordability needs in fertility care.

• For instance, in October 2024, Meitheal Pharmaceuticals expanded its biosimilar portfolio through collaboration with King-Friend Industry Co. to market and distribute follitropin alpha, a recombinant human FSH. The therapy is used to stimulate follicle development in women and spermatogenesis in men during fertility treatment.

The cetrorelix segment is projected to grow at a CAGR of 9.47% during the forecast period.

By Treatment

ART/IVF Cycle Support Segment Dominated Due to High Use of Fertility Drug Throughout IVF Treatment

Based on treatment, the market is segmented into ART/IVF cycle support, non-ART female fertility treatment, and male fertility treatment.

ART/IVF cycle support held the dominant position in the market. Fertility drugs are used at several stages of an IVF cycle, including ovarian stimulation, ovulation triggering, egg retrieval preparation, and luteal phase support. IVF requires more intensive medication use than non-ART fertility treatment, as patients typically need injectable gonadotropins, trigger drugs, GnRH agonists or antagonists, and progesterone support. This creates higher drug consumption per patient and makes ART/IVF cycle support the largest revenue-generating treatment segment.

• For instance, in February 2026, Kindbody launched its next-generation fertility platform, including a fertility medication portal to streamline authorizations, pharmacy fulfillment, delivery tracking, and medication education for patients. This shows how fertility care providers are strengthening medication support throughout IVF and family-building journeys, which supports the dominance of ART/IVF cycle-based drug use.

The male fertility treatment segment is projected to grow at a CAGR of 6.86% during the forecast period.

By Route of Administration

Injectable Segment Dominated Due to Precise Dosing and Better Ovarian Stimulation

Based on route of administration, the market is segmented into injectable, oral, vaginal, and others.

The injectable segment captured the highest market share, as many high-value fertility drugs, especially gonadotropins, hCG trigger drugs, and several GnRH therapies, are administered through injection. Injectable delivery allows fertility specialists to control dosing more precisely and achieve stronger ovarian stimulation than many oral therapies. Since IVF and controlled ovarian stimulation require close dose adjustment based on ovarian response, injectable medicines are preferred in clinic-led treatment cycles. Their higher price, repeated dosing requirement, and widespread use in ART protocols make injectable fertility drugs the leading segment.

• For instance, in May 2025, Gedeon Richter strengthened its collaboration with Granata Bio for fertility products, including co-development of Bemfola, Richter’s recombinant FSH product, for the U.S. market, and a royalty purchase agreement for Granata Bio’s hMG in the U.S. This development reflects continued company investment in injectable gonadotropin therapies used in fertility care.

The others segment is projected to grow at a CAGR of 10.48% over the forecast period.

By End User

Fertility Clinics Segment Dominated Due to Specialized Management of Fertility Treatment

Based on end user, the market is segmented into fertility clinics, hospitals, specialty clinics, homecare/self-administration settings, and others.

In 2025, fertility clinics dominated the market. Most fertility drug therapies, especially injectable hormonal stimulation drugs, require specialist supervision, ultrasound monitoring, hormone testing, and dose adjustments. IVF and IUI cycles are usually managed through fertility clinics. Since these clinics manage the highest number of ART cycles and directly control drug selection, they account for the largest share of fertility drug consumption. Expanding fertility clinic networks and consolidation among IVF providers further strengthen this segment’s dominance.

• For instance, in July 2025, IVI RMA Global announced the acquisition of ART Fertility Clinics’ operations in the UAE and Saudi Arabia, expanding its footprint in reproductive medicine across the GCC region. This development highlights how fertility clinic networks are expanding their presence, increasing patient access to IVF and fertility services while supporting higher utilization of fertility drugs.

The specialty clinics segment is projected to grow at a CAGR of 7.01% over the forecast period.

Fertility Drugs Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant fertility drugs market share in 2024, valued at USD 0.98 billion, and maintained its leading position in 2025, with USD 1.04 billion. The market is growing due to high infertility awareness, strong IVF adoption, and wider availability of fertility clinics. Better insurance/employer fertility benefits are also improving access to fertility drugs.

U.S. Fertility Drugs Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated to reach around USD 1.03 billion in 2026, accounting for roughly 31.71% of the global market.

Europe

Europe is projected to grow at a CAGR of 5.27% during the forecast period, the second-highest among all regions. The market is expected to reach a valuation of USD 0.87 billion in 2026. Growth in the European region is supported by established reproductive healthcare systems, rising maternal age, and increasing use of ART procedures. Public and private support for fertility care in several countries is helping sustain treatment demand.

U.K. Fertility Drugs Market

The U.K. market is estimated to reach USD 0.18 billion in 2026, accounting for roughly 5.41% of the global sales.

Germany Fertility Drugs Market

Germany's market is projected to reach approximately USD 0.20 billion in 2026, equivalent to around 6.13% of the global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 0.89 billion in 2026, securing the third-largest position in the market. The region is expanding rapidly due to delayed parenthood, rising infertility cases, and growing fertility clinic networks in countries such as China, India, Japan, and Australia. Lower treatment costs in some countries are also encouraging fertility tourism.

Japan Fertility Drugs Market

The Japanese market in 2026 is estimated to reach around USD 0.19 billion, accounting for approximately 6.01% of the global sales.

China's Fertility Drugs Market

China's market is projected to be among the largest worldwide, with 2026 revenues standing at around USD 0.27 billion, accounting for approximately 8.21% of global sales.

India Fertility Drugs Market

The Indian market is estimated to reach around USD 0.12 billion in 2026, accounting for roughly 3.84% of global revenues.

Latin America and the Middle East & Africa

The Latin America region is expected to witness moderate growth in this market during the forecast period. The market is estimated to reach a valuation of USD 0.19 billion in 2026. Market growth in the region is driven by growing awareness of infertility treatment and the gradual expansion of private fertility centers. Rising middle-class healthcare spending is increasing the use of IVF-related fertility drugs. In the Middle East & Africa, the GCC is set to reach USD 0.07 billion in 2026.

South Africa Fertility Drugs Market

The South African market is projected to reach approximately USD 0.02 billion in 2026, accounting for roughly 0.72% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

New Product Developments among Key Companies to Strengthen their Market Position

The presence of established pharmaceutical companies, women’s health specialists, and regional generic manufacturers offering hormonal therapies used across infertility treatment cycles defines the global market. Companies are focusing on expanding access to address the rising demand from fertility clinics and assisted reproductive technology centers. Companies are also strengthening their market position through new product approvals, biosimilar development, licensing agreements, affordability programs, and geographic expansion strategies. As IVF and IUI procedures continue to increase globally, manufacturers with broad fertility drug portfolios, strong clinical evidence, and convenient injectable formats are expected to maintain a leading role in the market.

• For instance, in October 2025, EMD Serono, the healthcare business of Merck KGaA in the U.S. and Canada, announced an agreement to expand access to its IVF therapy portfolio, including Gonal-f, Ovidrel, and Cetrotide, at reduced prices for eligible patients.

Major players such as Merck KGaA, Ferring Pharmaceuticals, and Organon & Co. are actively competing through product portfolio expansion, clinical development, biosimilar launches, licensing partnerships, and regional market penetration. Companies with strong exposure to injectable gonadotropins, recombinant FSH, GnRH antagonists, and luteal phase support drugs are expected to retain a higher market share due to their direct role in IVF and controlled ovarian stimulation protocols. In addition, rising infertility prevalence, delayed parenthood, growing fertility clinic networks, and increasing adoption of assisted reproductive technologies are encouraging key players to develop more affordable, convenient, and patient-focused fertility drug solutions.

LIST OF KEY FERTILITY DRUGS COMPANIES PROFILED

• Merck KGaA (Germany)
• Ferring B.V. (Switzerland)
• Organon & Co. (U.S.)
• IBSA Institut Biochimique SA (Switzerland)
• Gedeon Richter Plc. (Hungary)
• Theramex (U.K.)
• Livzon Pharmaceutical Group (China)
• LG Chem (South Korea)
• Bharat Serums and Vaccines (India)
• Lupin Limited (India)

KEY INDUSTRY DEVELOPMENTS

• February 2026: EMD Serono, the Healthcare business of Merck KGaA, announced new patient access pathways to make its complete portfolio of infertility medications used for in vitro fertilization (IVF), including Gonal-f, Ovidrel, and Cetrotide, more accessible to eligible patients with prescribed infertility in the U.S.
• October 2025: Ferring Pharmaceuticals announced new data for follitropin delta (FE 999049), an investigational-stage human recombinant follicle-stimulating hormone (rFSH) being studied to support the development of multiple follicles and improve pregnancy outcomes in ovulatory women undergoing fresh or frozen embryo transfer as part of an assisted reproductive technology (ART) cycle.
• July 2025: Organon acquired the MSD Biotech production site at De Geer in Oss. The acquisition expanded the company’s long-established presence in Oss and included all fertility activities and associated support roles. The drug substances for two of the company’s fertility products are manufactured at the Biotech Oss site.
• May 2025: Gedeon Richter Plc. collaborated with Granata Bio through a strategic investment and a binding term sheet for the U.S. co-development of Bemfola, a recombinant FSH fertility drug.
• September 2024: Organon group of companies collaborated with Shanghai Bao Pharmaceutical and its wholly-owned subsidiary, Suzhou Centergene Pharmaceuticals. The agreement granted Organon the exclusive commercialization rights to its investigational asset, SJ02, in Mainland China.
• May 2024: Apotex Corp. launched Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide in the U.S. Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonist, indicated for the prevention of premature LH surges in women undergoing controlled ovarian stimulation.

REPORT COVERAGE

The report provides a detailed assessment of the global fertility drugs market. The report highlights key drivers, trends, opportunities, restraints, and challenges shaping industry growth. Furthermore, the report also evaluates regional market performance across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with country-level insights where applicable. It includes an in-depth analysis of competitive developments such as product launches, partnerships, approvals, acquisitions, and expansion strategies adopted by key players. The study also examines the role of fertility clinics, hospitals, specialty clinics, and home care settings in supporting drug demand. In addition, the report provides market share analysis, growth outlook, and strategic insights to help stakeholders understand current demand patterns and future opportunities in the industry.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation